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| INTRODUCTION
Arginine vasopressin (AVP) or anti-diuretic hormone (ADH), commonly referred to as vasopressin, is a naturally occurring peptide with diverse effects in normal and stress physiology. Vasodilatory and septic shocks are associated with an absolute or relative deficiency of AVP and patients can be particularly sensitive to low-dose, exogenous AVP administration. [1] [2] [3] [4] AVP supplementation is safe in supporting patient hemodynamics while reducing the requirements and potential toxicities of high-dose catecholamines in the setting of septic shock. 5 A similar pathophysiologic vasodilatory state (vasoplegia) complicates 10% of cardiac surgery patients after cardiopulmonary bypass (CPB). 6 Retrospective and prospective studies examined the use AVP in this type of vasodilatory shock with varying results. Many surgical centers already routinely use AVP for the treatment of refractory vasodilatory shock; however, the data suggest that it can be used early and even routinely after CPB. 6 We provide an overview of AVP as it relates to cardiac surgery in the immediate post-operative period. We sought to identify the appropriate patient population as well as the correct timing of administration to obtain the maximum benefit from its use while minimizing potential adverse effects.
Taxonomy: Cardiac surgery; Hemodynamics; Pathophysiology; Cardiovascular Disease; Heart Failure.
| METHODS
Articles were selected as they related to the biochemistry, physiologic triggers, and prognostic value of AVP. A systematic literature search for relevant articles was performed through September 2018 using MEDLINE database. The search strategy was developed using the following key words and medical subject headings (MeSH) relating to the treatment (vasopressin, arginine vasopressin, copeptin, vasopressin analogue) and the population (thoracic surgery, cardiac surgical procedures, coronary artery bypass graft [CABG] , heart-assist devices, ventricular assist device [VAD] , cardiopulmonary bypass, vasoplegia).
Citations were limited to original research performed in humans and published in the English language. A manual search of references from review articles was also performed to identify additional relevant studies. Article titles were screened for potential inclusion. If the citation was potentially eligible for inclusion, the full-text version was reviewed. Full citations were included if they enrolled adult patients in the aforementioned populations, compared AVP to catecholamines or placebo, and evaluated hemodynamic parameters.
A total of 296 articles were screened. Two hundred forty-six were excluded in the initial screening process. Fifty-five of these articles were commentary or case reports. One hundred seventy-seven were not in adults and did not directly compare AVP to catecholamines or
placebo. An additional 15 articles were not related to the CV surgical population. Fifty articles were selected for full-text review. Of these 15
were excluded as case reports or commentary and 21 were excluded due to patient population or lack of comparison to placebo or catecholamines. Fourteen articles were included in the final review ( Figure 1 ).
| Mechanism of action and physiology
AVP is synthesized as pre-provasopressin and subsequently cleaved into AVP, copeptin, and neurophysin II. 7 AVP is stored in neurosecretory vesicles with copeptin in the posterior pituitary. It is thought that 10-20% of total AVP stores are available for immediate use in normal states. 8 AVP's physiologic effects are mediated through its interactions with three distinct cellular receptors. The first receptor, V1 (previously V1a) is located primarily on smooth muscle in the vasculature as well as the gastrointestinal tract. It activates phospholipase C which causes calcium release from the sarcoplasmic reticulum, thereby increasing smooth muscle tone. 9 Through actions on the V1 receptor, AVP serves as a vasoconstrictor. The V1 receptor is also located on platelets and can promote platelet aggregation as well as the release of procoagulants (factor VIIIa and von Willebrand factor) from the vascular endothelium. 9 The V2 receptor is present in the distal tubule and collecting ducts in renal nephrons. Agonism at this level increases intracellular cyclic adenosine monophosphate and activates protein kinase A. The result of this is increased volume and increased systemic extracellular fluid. 9 The final receptor, V3 (formerly V1b), is located in both the pituitary gland and the pancreas. Activation stimulates release of adrenocorticotropic hormone. 10 In healthy volunteers, the circulating levels of AVP are below the threshold for vasoconstriction. 9 The typical triggers of AVP release are decreased blood volume (through activation of arterial baroreceptors) and increased serum osmolarity. Additional triggers for release include several types of physiologic stress including hypoxia, acidosis, infection, hypoglycemia, pain, nausea, and vomiting. 
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Several synthetic analogues of AVP have been developed, including desmopressin and terlipressin. Desmopressin is a long-acting AVP analogue with minimal vasopressor activity and is primarily used in bleeding disorders and in diabetes insipidus. 9 Terlipressin has selective V1 activity with a half-life of six hours. Terlipressin is delivered intravenously as a pro-drug and is broken down to the active ingredient (lysine-vasopressin) by endopeptidases. The TERLIVAP trial in humans suffering septic shock suggested a benefit to terlipressin FIGURE 1 Article selection for systematic review. Figure 1 provides a flow sheet of articles that were screened and selected for inclusion in the systematic review. Articles selected for inclusion were of original research (not commentary or case studies) of inadult, human trials comparing the relative hemodynamic effects of arginine vasopressin versus catecholamines (namely norepinephrine) or placebo in the cardiovascular surgery population over AVP when added to norepinephrine but concerns about negative effects on cardiac output remained. 13 A meta-analysis of its role suggested that high doses of terlipressin have detrimental effects on cardiac output, oxygen delivery, and consumption. The drug is currently unavailable in the United States.
14 Antagonists of vasopressin receptors have also been developed.
Tolvaptan is a selective V2 antagonist and is used to treat hyponatremia in syndrome of inappropriate anti-diuretic hormone secretion. The EVEREST trial investigated the efficacy of tolvaptan in patients hospitalized with heart failure whose AVP levels were known to be elevated. When added to standard medical therapy, tolvaptan raised serum sodium without significant improvement in mortality or outcomes. 18 
| Copeptin
Measurement of circulating AVP is fraught with complications and is not suited for routine use. AVP is highly unstable ex vivo. It is rapidly cleared from serum even when stored at −20°C. 15 AVP is largely bound to platelets (90%) and incomplete platelet removal from samples will lead to falsely elevated levels. AVP is released in 1:1 equimolar amounts with copeptin, a molecule more easily measured. 10 Copeptin is a 39-amino acid glycoprotein, which helps to make up AVP's precursor molecule: pre-provasopressin. 15 Copeptin is used to shuttle AVP into the hypothalamic vesicles but its physiologic role in circulation is unclear. It is known that copeptin levels rise and fall with AVP levels ( Figure 2 ). 10 Copeptin is highly stable with a much longer half-life than AVP. It can also be preserved in EDTA phlebotomy tubes for several days at room temperature. Sandwich immunoluminometric assay is a highly reliable and reproducible way to measure copeptin levels as a surrogate of circulating AVP. 15 Normal copeptin levels range between 1.7 and 11.25 pmol/L with an average of 4.2 pmol/L. This varies for men and women with the male average 5.2 pmol/L and the female average 3.7 pmol/L. 16 AVP and copeptin levels are chronically elevated in heart failure with reduced ejection fraction and correlate well with cardiac index, ejection fraction and serum B-type natriuretic peptide (BNP). 17 Treatment of advanced heart failure with heart transplant or left ventricular assist device leads to subsequent reductions in these levels. 17 AVP and copeptin are prognostic of short and long-term mortality across the spectrum of heart failure being most accurate in New York Heart Association class II and III patients. 19, 20 When combined with N-terminal proBNP and diastolic blood pressure, it proved accurate in predicting 5-year mortality. 21 
| Relative deficiency and risk factors
In the cardiac surgery population, blood exposure to abnormal surfaces as is seen in cardiopulmonary bypass (CPB) is associated with a systemic inflammatory response. 22 Levels of AVP and copeptin after cardiopulmonary bypass are significantly higher than pre-bypass. The serum levels appear to peak on postop day (POD) 1. These levels are also significantly higher than in other stress states such as sepsis or non-cardiac surgery. and were more likely to have had a history of hypothyroidism. 28 In this study, the use of pre-and postoperative milrinone (a known vasodilator) was associated with less vasoplegia.
Lastly, a study by Colson et al demonstrated preoperative
copeptin levels as an independent predictor of postoperative AVP deficiency. Using a cutoff of 37.9 pg/mL (9.43 pmol/L), the marker had a sensitivity of 90% and a specificity of 77% with a 43% positive predictive value and a 98% negative predictive value. in this population. AVP had no apparent effect on VAD flows, inotrope requirements or pulmonary artery pressure. 31 It should be noted that digital and limb ischemia was seen in 6% of these patients and cardiac output was decreased at very high doses (0.6 U/min).
Another study of combination therapy was performed by Dunser et al in which patients were randomized to norepinephrine (NE) vs.
norepinephrine and AVP at a rate of 0.067U/min. The patients in the AVP + NE group had significantly higher MAP, significantly lower heart rates as well as less tachyarrythmias (8.3% vs 54.3%) compared to the NE monotherapy group. 32 Furthermore, cardiac index and stroke volume were significantly higher in the AVP + NE group. In this study, however, SVR was not significantly different between the two groups.
It should be noted that the AVP +NE group had significantly reduced platelets and higher total bilirubin when compared with NE monotherapy. 32 These studies demonstrate the utility of AVP administration with norepinephrine when vasodilatory shock has been identified. Alternative mechanisms such as activation of potassium-dependent ATP channels and excessive nitric oxide (NO) production must also be considered. 33 There are fewer data to support AVP as monotherapy for vasoplegia post-cardiopulmonary bypass. Yimin et al studied the differences between NE and AVP monotherapies for hypotension in 20 patients undergoing CABG. There was no significant differences between the two therapies but the pulmonary artery pressures were higher in the norepinephrine group. 36 One of the largest prospective studies to examine this was the VANCS trial, which randomized 330 patients with post-CPB vasodilatory shock to norepinephrine (10- 
| Adverse effects
Renal failure is a complication of AVP administration; however, at low doses (0.01-0.04 U/min), this is extremely rare. 33 Higher doses up to 0.1U/min are well tolerated (which correlates to a plasma concentration of 150 pg/mL, 138 pmol/L). Infusions of 0.01 U/min correlate with plasma levels <40 pg/mL or physiologic replacement. 6 One study of 280 patients undergoing CABG with AVP monotherapy showed a dose-dependent incidence of acute kidney injury. 38 It should be noted that this was a retrospective study and the indications for AVP administration were not clearly defined. It is unclear if the AKI was secondary to the hypotension that may have preceded the use of AVP.
Furthermore, doses in this study were very high, reaching 1 U/min, 10× the maximal dose used in studies showing efficacy.
Another complication of AVP administration is the development intestinal ischemia. A study by Nygren and colleagues used Doppler flowmetry to measure jejunal mucosal perfusion in the setting of AVP use in vasodillatory shock. Increased AVP was associated with a 20% reduction in mucosal perfusion and increased arterial-gastric mucosal CO2 gradient. 39 In addition porcine models show that gastric blood flow is decreased with cardiopulmonary bypass. These effects were exacerbated by the addition of AVP. 40 Porcine models showed similar group; however, it remained unchanged in the AVP group. 43 Okamoto et al studied changes in CK-MB and troponin post AVP use. They demonstrated no elevation in cardiac enzymes in either the norepinephrine or AVP groups 12 hr after surgery. 33 Therefore, it seems that at currently accepted doses of less than or equal to 0.1 units/hour, the risk of cardiac ischemia is nominal.
Lastly, there are mixed data to suggest whether AVP negatively affects cardiac output. In a porcine model of cardiogenic shock, the combination of NE and dobutamine was superior to AVP and dobutamine. The dobutamine/AVP combination increased SVR;
however, the increased afterload decreased cardiac output and exacerbated pump failure. 44 In human studies of patients with mildly reduced left ventricular ejection fraction, AVP administration during separation from cardiopulmonary bypass resulted in better cardiac indices compared to placebo. Patients also had a significant increase in ejection fraction compared to baseline and placebo. 45 This suggests that the increased afterload may be offset by increased preload and/or increased myocardial contractility through direct action of AVP on myocytes. The combination of AVP with traditional catecholamines limits the need for increased doses of catecholamines and can lead to improved heart rate, improved myocardial oxygen demand, and lower rates of cardiac arrhythmias. Many factors other than the absolute and relative deficiences of AVP contribute to vasodilatory shock, which explains why AVP therapy is ineffective in some patients.
Further studies are necessary to determine whether the routine use of AVP in all cardiac surgery patients will have a role in preventing vasoplegic syndromes following CPB. 
